Purpose: A tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to immunotherapy. However, methods that promote TLS formation are limited and challenging to implement in clinical settings. In this study, we aimed to promote the formation and maturation of TLSs in lung adenocarcinoma (LUAD) by combining low-dose radiotherapy (LDRT) with immunotherapy.Methods: Tissue sections from 198 patients who had undergone surgery were examined. Risk factors for patient survival were assessed, and the relationship between TLSs and five-year survival was analyzed. The Kras-LSL-G12D spontaneous lung cancer mouse model was used to screen the optimal irradiation dose (0/1/2 Gy whole lung irradiation) for promoting TLS formation. LDRT combined with anti-PD-1 was used to promote the formation and maturation of TLSs.Results: TLS+, TLSHigh, TLS+GC+ and CD8High within TLS+ were associated with a favorable prognosis. LDRT increased the formation of early TLSs in the Kras-LSL-G12D lung cancer mouse model. In addition, LDRT combined with anti-PD-1 treatment can significantly improve the maturity of TLSs in mouse LUAD, resulting in greater antitumor effects. This antitumor effect was strongly associated with the number of CD8+ T cells within the TLSs.Conclusion: We successfully applied LDRT combined with PD-1 inhibitor therapy for the first time, which increased both the quantity and maturity of TLSs in lung cancer. This approach achieved a promising antitumor effect.
Background: Engineered extracellular vesicles (EVs) are emerging as a highly potential platform for targeted drug delivery in cancer therapy. Although intravenous injection is commonly used in EV treatment, there is growing interest in using microneedles (MNs) for transdermal EV delivery; however, comprehensive studies comparing the tissue distribution, safety and antitumour efficacy of these two approaches for delivering engineered EVs remain scarce.Methods: We used EVs derived from umbilical cord mesenchymal stem cells, modified with phospholipid‒polyethylene glycol‒N‐hydroxysuccinimide and conjugated with CD38 peptides (CD38‐EVs), to target myeloma cells that highly express CD38 antigen, and tested their safety and antitumour efficacy in mice with subcutaneous plasmacytoma, administrated via dissolvable transdermal MNs or intravenous injection. Flow cytometry, immunofluorescence and fluorescence molecular projection imaging analysis were employed to evaluate the distribution of CD38‐EVs at the cellular level and within living systems. Additionally, histopathological analysis and biochemical analyses were conducted to assess the antitumour effects and safety of CD38‐EVs loaded with doxorubicin (CD38‐EVs‐Dox).Results: Compared to standard EVs, CD38‐EVs exhibited enhanced uptake by CD38high tumour cells and reduced uptake by CD38‐negative non‐tumour cells in vitro. In plasmacytoma NOD/SCID mouse models, CD38‐EVs encapsulated within MNs (CD38‐EVsMNs) effectively targeted the tumour cells much more than the standard EVs encapsulated within MNs (EVsMNs) and CD38‐EVs intravenously administrated (CD38‐EVsi.v), with reduced distribution to the lungs and spleen. Additionally, CD38‐EVs‐Dox induced significantly greater cytotoxicity against the tumour cells than EVs‐Dox in vitro, and CD38‐EVs‐DoxMNs significantly reduced tumour burden compared to both EVs‐DoxMNs and CD38‐EVs‐Doxi.v, while maintaining favourable safety profiles.Conclusions: CD38‐EVs‐DoxMNs have superior efficacy and safety in treating plasmacytoma mice, compared to CD38‐EVs‐Doxi.v, providing novel insights into the potential of MNs as a platform for delivering targeted engineered EVs in tumour therapy.Highlights: Enhanced tumor targeting: CD38‐modified EVs (CD38‐EVs) showed increased uptake by CD38high tumor cells while reducing uptake by CD38‐negative non‐tumor cells. Optimized delivery: MN‐loaded CD38‐EVs targeted tumors more effectively than MN‐loaded EVs and intravenously injected CD38‐EVs, with lower lung and spleen accumulation. Superior antitumor efficacy: MN‐delivered CD38‐EVs‐Dox significantly suppressed tumor growth, outperforming intravenous CD38‐EVs‐Dox and MN‐delivered EVs‐Dox.
Supervised learning’s reliance on high-fidelity labeled data limits its application in fluorescence diffusion tomography (FDT). Here, we propose a multi-operator-based model-driven self-supervised learning (MMSL) for FDT to eliminate the need for labeled data. Our approach exploits geometrically disjoint source–detector configurations to derive two forward operators from the photon transport model while integrating the operators as dual constraints into an unrolled network architecture: one enforces output-space consistency, and the other directs network parameter optimization. Experimental results on our custom-built line-illumination FDT system demonstrate that MMSL achieves reconstruction quality comparable to supervised methods while exhibiting superior recovery of morphological features. This advancement significantly expands the practical utility of deep learning in experimental FDT scenarios lacking labeled data.
Umbilical cord mesenchymal stem cell-derived extracellular vesicles (UCMSC-EVs) hold strong promise for regenerative medicine, yet their intrinsic size heterogeneity remains a critical barrier to clinical translation, as it obscures molecular and functional specialization within bulk EV preparations. Here, we pioneer the application of the automated EXODUS platform to directly fractionate EVs from cell culture supernatants, resolving bulk UCMSC-EVs into three size-defined subpopulations. By integrating this platform with high-resolution mass spectrometry, we systematically characterize the molecular and functional landscapes of these UCMSC-EV size subpopulations. We demonstrate that EV size is tightly linked to distinct biogenetic origins, biomolecular corona composition, and functional programs: smaller EVs are enriched in exosome-associated proteins, ECM–glycan interfaces, and corona-associated molecules, and preferentially engage endocytosis- and phagosome-related pathways, whereas larger EVs exhibit ectosomal signatures. These findings identify EV size as a critical determinant of molecular architecture and biological function, providing insight into size-dependent EV heterogeneity and informing the rational design and optimization of UCMSC-EV-based therapeutic strategies.